ArticleBMJ open ophthalmology2025
High-risk features in retinoblastoma: the association between histopathology and MRI.
Article in BMJ open ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanoprobe-Enabled Precision Imaging and Panoramic Boundary Delineation in Retinoblastoma.Cancer innovation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdentification of high-risk features is essential for improving treatment outcomes of retinoblastoma. MRI is one of the most used modalities in treatment decision-making; however, its accuracy in detecting extension into different ocular structures is variable. This study aims to evaluate high-risk features in retinoblastoma by comparing MRI with histopathology results. METHODOLOGY: This was a retrospective chart review of patients enrolled in the retinoblastoma programme at the American University of Beirut Medical Center from November 2012 to December 2022. We included enucleated eyes, classified as group D or E per the International Intraocular Retinoblastoma Classification. Data pertaining to high-risk features (including postlaminar optic nerve (ON) and massive choroidal invasion) were collected from preoperative MRI and histopathological examination following enucleation. Data on scleral and anterior segment involvement (not considered high-risk features) were also collected. Morphometric properties were calculated and analysed.
resultsAnalysis included 48 eyes from 44 patients. Males constituted 52.1% (n=25) of the sample and females 47.9% (n=23). 58% had unilateral retinoblastoma. The median age at diagnosis was 14.5 months (10-34.5). The median follow-up period from the first visit to data collection was 27.5 months (17.3-49). On tissue examination, 3 patients had postlaminar ON involvement and 11 had massive choroidal involvement. For postlaminar ON involvement, the MRI showed a moderate sensitivity (66.7%) and specificity (71.1%), with a high negative predictive value (NPV) of 96.9% but a low positive predictive value (PPV) of 13.3%. In cases of massive choroidal invasion, MRI demonstrated moderate sensitivity (45.5%) and specificity (75.7%), with a good NPV of 82.4% but a low PPV of 35.7%. Additionally, histopathology identified anterior segment involvement in six cases and scleral involvement in two cases. MRI showed high accuracy in detecting invasion of the anterior chamber (79.2%) and moderate accuracy in detecting invasion of the sclera (62.5%).
conclusionMRI showed high levels of variability in detecting high-risk features in advanced retinoblastoma. MRI results ought to be interpreted with caution when making treatment decisions in advanced retinoblastoma. Limitations of our study included a relatively small sample size, retrospective design and possible technical constraints of MRI imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.